fda warning letters glp-1 compounding october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA warning letters target marketers

Dedhia says timing is everything

They work well for users seeking comprehensive peptide exposure without managing multiple single-peptide products

Neuroprotective Effects of IV Glutathione Several studies have explored the neuroprotective properties of IV glutathione administration

Nevertheless, it is prudent to have regular medical supervision, so any subtle interaction or side effects can be promptly identified and managed appropriately

Your healthcare provider will consider the reason you are stopping, how long you have been taking your current medication, and the date of your last dose when deciding the best way to switch between these medications

Q5: Are there any side effects of L-Carnitine